{
    "clinical_study": {
        "@rank": "48506", 
        "arm_group": [
            {
                "arm_group_label": "Eplerenone", 
                "arm_group_type": "Experimental", 
                "description": "oral daily treatment with doses 100 to 400 mg"
            }, 
            {
                "arm_group_label": "Spironolactone", 
                "arm_group_type": "Active Comparator", 
                "description": "oral daily treatment with doses 100 to 400 mg"
            }
        ], 
        "brief_summary": {
            "textblock": "This study compares Spironolactone, a non-selective aldosterone antagonist, with Eplerenone,\n      a selective aldosterone antagonist, regarding efficacy and hormonal side effects when\n      treating male cirrhotic patients with uncomplicated ascites over a 6 month period. The\n      investigators hypothesis is that Eplerenone is as effective as Spironolactone as treatment\n      of ascites with less side effects such as painful gynecomastia."
        }, 
        "brief_title": "Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis; a Study of Efficacy and Side Effects", 
        "condition": [
            "Ascites", 
            "Cirrhosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Ascites", 
                "Liver Cirrhosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Male Ascites Cirrhosis\n\n        -\n\n        Exclusion Criteria:\n\n        Prior treatment with aldosterone antagonist Uncontrolled heart disease or diabetes Current\n        malignancy Current medication interacting with aldosterone antagonists"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01801228", 
            "org_study_id": "2011-001264-22", 
            "secondary_id": "2011-001264-22"
        }, 
        "intervention": {
            "arm_group_label": [
                "Eplerenone", 
                "Spironolactone"
            ], 
            "intervention_name": "Eplerenone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Spironolactone", 
                "Eplerenone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 27, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lund", 
                        "country": "Sweden", 
                        "state": "Skane", 
                        "zip": "221 85"
                    }, 
                    "name": "University Hospital of Skane"
                }, 
                "investigator": {
                    "last_name": "Emma Nilsson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lund", 
                        "country": "Sweden", 
                        "state": "Skane", 
                        "zip": "221 85"
                    }, 
                    "name": "University Hospital of Skane"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "official_title": "Swedish, Multicentered, Randomized Study of Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis Regarding Efficacy and Side Effects", 
        "overall_contact": {
            "email": "emma.nilsson@skane.se", 
            "last_name": "Emma Nilsson, MD", 
            "phone": "+4646177706"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Ascites", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01801228"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Region Skane", 
            "investigator_full_name": "Emma Nilsson", 
            "investigator_title": "Gastroenterologist", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Region Skane", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "G\u00f6teborg University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Uppsala University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Karolinska University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University Hospital, Linkoeping", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University Hospital, Ume\u00e5", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University Hospital Orebro", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Emma Nilsson", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}